Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, Payne R, Powlson J, Bliss C, Venkatraman N, Poulton ID, de Graaf H, Gbesemete D, Grobbelaar A, Davies H, Roberts R, Angus B, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee C, Ockenhouse C, Sinden RE, Gerry SC, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Lewis DJM, Cooke GS, Faust SN, Gilbert S, Hill AVS.

NPJ Vaccines. 2018 Oct 9;3:49. doi: 10.1038/s41541-018-0084-2. eCollection 2018.

2.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM, Poulton ID, de Graaf H, Sukhtankar P, Roberts R, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee CK, Ockenhouse CF, Sinden RE, Gerry S, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Cooke GS, Faust SN, Gilbert S, Hill AV.

J Infect Dis. 2016 Sep 1;214(5):772-81. doi: 10.1093/infdis/jiw244. Epub 2016 Jun 15.

3.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J.

J Infect Dis. 2016 Sep 1;214(5):762-71. doi: 10.1093/infdis/jiw237. Epub 2016 Jun 13.

PMID:
27296848
4.

Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.

Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, Paolino K, Moon J, Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin R, Wille-Reece U, Sedegah M, Hendriks J, Versteege I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J.

PLoS One. 2015 Jul 6;10(7):e0131571. doi: 10.1371/journal.pone.0131571. eCollection 2015.

5.

Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies.

Sirskyj D, Weltzin R, Golshani A, Anderson D, Bozic J, Diaz-Mitoma F, Azizi A.

J Virol Methods. 2010 Feb;163(2):459-64. doi: 10.1016/j.jviromet.2009.11.014. Epub 2009 Nov 11.

PMID:
19913054
6.

Rapid detection of anti-hepatitis A virus neutralizing antibodies in a microplate enzyme immunoassay.

Azizi A, Sirskyj D, Weltzin R, Anderson DE, Diaz-Mitoma F.

J Med Microbiol. 2009 Nov;58(Pt 11):1433-6. doi: 10.1099/jmm.0.012203-0. Epub 2009 Jul 16.

PMID:
19608692
7.

The therapeutic potential of monoclonal antibodies against respiratory syncytial virus.

Weltzin R.

Expert Opin Investig Drugs. 1998 Aug;7(8):1271-83.

PMID:
15992030
8.

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T, Nichols R, Weltzin R.

Int J Infect Dis. 2004 Oct;8 Suppl 2:S31-44. Review.

9.

Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.

Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, Nichols R, Johnson C, Cruz J, Kennedy JS, Ennis FA, Monath TP.

Nat Med. 2003 Sep;9(9):1125-30. Epub 2003 Aug 17.

PMID:
12925845
10.

Development of a novel vaccinia-neutralization assay based on reporter-gene expression.

Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, Merchlinsky M, Eller N, Mikolajczyk MG, Clanton DJ, Monath T, Weltzin RA, Scott DE, Golding H.

J Infect Dis. 2003 Aug 1;188(3):440-8. Epub 2003 Jul 16.

PMID:
12870127
11.

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP.

Virology. 2002 Jun 20;298(1):146-59.

12.

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP.

J Virol. 2001 Aug;75(16):7290-304.

13.

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP.

J Virol. 2000 Jun;74(12):5477-85.

14.
15.

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, Barrett AD, Nichols R, Weltzin R, Arroyo J, Guirakhoo F.

J Virol. 2000 Feb;74(4):1742-51.

16.

Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori.

Lee CK, Soike K, Giannasca P, Hill J, Weltzin R, Kleanthous H, Blanchard J, Monath TP.

Vaccine. 1999 Aug 6;17(23-24):3072-82.

PMID:
10462242
17.

Intranasal antibody prophylaxis for protection against viral disease.

Weltzin R, Monath TP.

Clin Microbiol Rev. 1999 Jul;12(3):383-93. Review.

18.

Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.

Lee CK, Soike K, Hill J, Georgakopoulos K, Tibbitts T, Ingrassia J, Gray H, Boden J, Kleanthous H, Giannasca P, Ermak T, Weltzin R, Blanchard J, Monath TP.

Vaccine. 1999 Mar 17;17(11-12):1493-505.

PMID:
10195786
19.

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.

Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP.

J Exp Med. 1998 Dec 21;188(12):2277-88.

20.

Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection.

Weltzin R, Kleanthous H, Guirakhoo F, Monath TP, Lee CK.

Vaccine. 1997 Mar;15(4):370-6.

PMID:
9141207
21.
22.
23.

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.

Weltzin R, Traina-Dorge V, Soike K, Zhang JY, Mack P, Soman G, Drabik G, Monath TP.

J Infect Dis. 1996 Aug;174(2):256-61.

PMID:
8699052
24.

Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis.

Lee CK, Weltzin R, Thomas WD Jr, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP.

J Infect Dis. 1995 Jul;172(1):161-72.

PMID:
7797906
25.

Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice.

Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP.

Antimicrob Agents Chemother. 1994 Dec;38(12):2785-91.

26.

Oral administration of polymeric immunoglobulin A prevents colonization with Vibrio cholerae in neonatal mice.

Lee CK, Weltzin R, Soman G, Georgakopoulos KM, Houle DM, Monath TP.

Infect Immun. 1994 Mar;62(3):887-91.

27.

M cell-mediated antigen transport and monoclonal IgA antibodies for mucosal immune protection.

Amerongen HM, Weltzin R, Mack JA, Winner LS 3rd, Michetti P, Apter FM, Kraehenbuhl JP, Neutra MR.

Ann N Y Acad Sci. 1992;664:18-26. Review. No abstract available.

PMID:
1456648
28.
29.

Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS.

Amerongen HM, Weltzin R, Farnet CM, Michetti P, Haseltine WA, Neutra MR.

J Acquir Immune Defic Syndr. 1991;4(8):760-5.

PMID:
1856788
30.

Production and use of monoclonal IgA antibodies complexed with recombinant secretory component for passive mucosal protection.

Michetti P, Hirt R, Weltzin R, Fasel N, Schaerer E, Neutra MR, Kraehenbühl JP.

Adv Exp Med Biol. 1991;310:183-5. No abstract available.

PMID:
1808996
31.

Identification and use of protective monoclonal IgA antibodies against viral and bacterial pathogens.

Neutra M, Weltzin R, Winner L, Mack J, Michetti P, Morrison L, Fields BN, Mekalanos JJ, Kraehenbuhl JP.

Adv Exp Med Biol. 1991;310:179-82. No abstract available.

PMID:
1808995
32.

Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins.

Weltzin R, Lucia-Jandris P, Michetti P, Fields BN, Kraehenbuhl JP, Neutra MR.

J Cell Biol. 1989 May;108(5):1673-85.

33.

Membrane domains and macromolecular transport in intestinal epithelial cells.

Neutra MR, Wilson JM, Weltzin RA, Kraehenbuhl JP.

Am Rev Respir Dis. 1988 Dec;138(6 Pt 2):S10-6.

PMID:
3202517
34.

Receptor-mediated transepithelial transport of secretory antibodies and engineering of mucosal antibodies.

Kraehenbuhl JP, Schaerer E, Weltzin R, Solari R.

Adv Exp Med Biol. 1987;216B:1053-60. No abstract available.

PMID:
3425415
35.

A role for calcium-activated calmodulin in murine nonspecific cell-mediated cytotoxicity.

Weltzin R, Fan S, Cain CA, Tompkins WA.

Immunopharmacology. 1983 Jun;6(1):37-49.

PMID:
6307925
36.

Enhanced cytotoxicity of mouse natural killer cells for vaccinia and herpes virus-infected targets.

Piontek GE, Weltzin R, Tompkins WA.

J Reticuloendothel Soc. 1980 Feb;27(2):175-88. No abstract available.

PMID:
6244409

Supplemental Content

Loading ...
Support Center